The goal of this clinical trial is to determine the effectiveness of azathioprine (AZA) versus mycophenolate mofetil (MMF) in inducing remission in treatment-naive patients with autoimmune hepatitis (AIH). The main questions it aims to answer are:
Does MMF combined with prednisolone lead to higher remission rates compared to AZA with prednisolone after 24 weeks? Is MMF associated with fewer adverse events than AZA in these patients? Researchers will compare two treatment arms (MMF vs. AZA) to see if MMF leads to improved remission rates and safety outcomes.
Primary Outcome Measure:
Biochemical remission: The primary outcome is the normalization of liver enzymes (AST, ALT) and IgG levels at 24 weeks.
Secondary Outcome Measures:
Safety and adverse events: Monitoring and comparing the incidence and severity of side effects between the two groups.
Treatment adherence: Evaluating how well patients stick to their assigned treatment regimens.
Improvement in quality of life: Assessing changes in the patient's quality of life using validated questionnaires.
Reversal of fibrosis: Measured by liver stiffness using Fibroscan, aiming for no progression of fibrosis.
Participants will:
Receive either MMF or AZA, alongside a tapering dose of prednisolone. Be monitored regularly through clinic visits, laboratory tests, and safety assessments to track remission and any adverse events.

Start Date01 Nov 2024

Sponsor / Collaborator

Institute of Liver & Biliary Sciences

CTR20243835 / Active, not recruitingNot Applicable

硫唑嘌呤片在健康人体空腹状态下的随机、开放、双周期、双交叉设计生物等效性试验

[Translation] A randomized, open-label, two-period, double-crossover bioequivalence study of azathioprine tablets in healthy volunteers under fasting conditions

本研究以上海上药信谊药厂有限公司持证的硫唑嘌呤片为受试制剂，以Excella GmbH & Co. KG生产的硫唑嘌呤片（依木兰）为参比制剂，进行空腹状态下的人体生物等效性试验，评价受试制剂和参比制剂在健康受试者体内的生物等效性，同时观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

This study used the certified azathioprine tablets produced by Shanghai Haiyao Xinyi Pharmaceutical Co., Ltd. as the test preparation and the azathioprine tablets (Imuran) produced by Excella GmbH & Co. KG as the reference preparation to conduct a human bioequivalence study under the fasting state to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects and observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date23 Oct 2024

Sponsor / Collaborator

Shanghai Sine Pharmaceutical Co. Ltd.

100 Clinical Results associated with Azathioprine

100 Translational Medicine associated with Azathioprine

100 Patents (Medical) associated with Azathioprine

16,852

Literatures (Medical) associated with Azathioprine

01 Apr 2025·DEN open

Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?

Article

Author: Shimodate, Yuichi ; Nishimura, Naoyuki ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro

Abstract:

A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.

31 Dec 2024·Future Science OA

Overlap syndrome of seronegative primary biliary cholangitis and small duct primary sclerosing cholangitis: a first case report and literature review

Author: Serghini, Meriem ; Souissi, Salma ; Laabidi, Asma ; Mustpha, Nadia Ben ; Boubaker, Jalel ; Chelly, Ines ; Fekih, Monia ; Laabidi, Sarah

Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) are distinct liver diseases. Cases combining PBC and PSC, are extremely rare. Here, we present a case of a 39-year-old woman with a history of colonic Crohn's disease treated with azathioprine. Discontinuation of the medication was prompted by abnormal liver function tests, but subsequent evaluations revealed persistent liver injury. Extensive diagnostic investigations, including imaging, serological tests, and liver biopsy, were conducted leading to a diagnosis of PBC-PSC overlap syndrome based on the presence of concentric lamellar fibrosis and chronic non-suppurative destructive cholangitis. The patient responded well to ursodeoxycholic acid treatment. This case emphasizes the importance of recognizing and diagnosing rare overlap syndromes, particularly those involving PBC and PSC, to ensure appropriate management and improve patient outcomes.

31 Dec 2024·JOURNAL OF DERMATOLOGICAL TREATMENT

Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network

Article

Author: Ständer, Sascha ; Thaçi, Diamant ; Ludwig, Ralf J. ; Zirpel, Henner ; Kridin, Khalaf ; Olbrich, Henning

BACKGROUND:

Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.

OBJECTIVE:

To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.

METHODS:

Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX US Collaborative Network. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.

RESULTS:

5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.

CONCLUSION:

Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.

102

News (Medical) associated with Azathioprine

03 Dec 2024

·www.prnewswire.com

Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D. Heightened awareness and robust support from governments and key industry players further create a dynamic environment for innovation and better patient outcomes. LAS VEGAS, Dec. 3, 2024 /PRNewswire/ -- DelveInsight's ' Lupus Nephritis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline lupus nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the lupus nephritis pipeline domain. Key Takeaways from the Lupus Nephritis Pipeline Report DelveInsight's lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for lupus nephritis treatment. Key lupus nephritis companies such as AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others are evaluating new lupus nephritis drugs to improve the treatment landscape. Promising lupus nephritis pipeline therapies such as Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others are under different phases of lupus nephritis clinical trials. In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases. In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease. In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report The lupus nephritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lupus nephritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lupus nephritis clinical trial landscape. Lupus Nephritis Overview Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that can affect multiple organ systems. In lupus nephritis, the immune system mistakenly attacks the kidneys, leading to inflammation and damage. The exact cause is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors, including infections and exposure to certain drugs or UV light. Symptoms of lupus nephritis can vary but often include swelling in the legs and feet, high blood pressure, foamy urine, and in severe cases, hematuria. Patients may also experience fatigue, joint pain, and skin rashes, typical of lupus. Diagnosis usually involves a combination of blood tests, urinalysis, and imaging studies. A kidney biopsy may be necessary to evaluate the extent of kidney damage and guide treatment. Treatment for lupus nephritis aims to reduce inflammation and prevent kidney damage. It often involves corticosteroids and immunosuppressive medications such as mycophenolate mofetil or azathioprine. In severe cases, more aggressive treatments, including cyclophosphamide or biologic therapies like belimumab, may be utilized. Regular monitoring of kidney function and overall health is crucial for managing the disease effectively. Find out more about lupus nephritis treatment drugs @ Drugs for Lupus Nephritis Treatment A snapshot of the Lupus Nephritis Pipeline Drugs mentioned in the report: Learn more about the emerging lupus nephritis pipeline therapies @ Lupus Nephritis Clinical Trials Lupus Nephritis Therapeutics Assessment The lupus nephritis pipeline report proffers an integral view of the lupus nephritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Lupus Nephritis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Interferon alpha-beta receptor antagonists, Cell death inhibitors, Cell death stimulants, Antibody-dependent cell cytotoxicity, B-cell activation factor receptor antagonists, Glucokinase stimulants, Dendritic cell inhibitors, Complement factor D inhibitors, Complement C3 inhibitors, Proteasome inhibitors, Natural killer cell replacements, Immunologic cytotoxicity; T lymphocyte replacements Key Lupus Nephritis Companies: AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others. Key Lupus Nephritis Pipeline Therapies: Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others. Dive deep into rich insights for new drugs for lupus nephritis treatment, visit @ Lupus Nephritis Drugs Table of Contents For further information on the lupus nephritis pipeline therapeutics, reach out @ Lupus Nephritis Treatment Drugs Related Reports Lupus Nephritis Epidemiology Lupus Nephritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted lupus nephritis epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, CABALETTA BIO, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

IND

03 Dec 2024

·www.accesswire.com

Liver Transplant Market Poised for Significant Growth, projected to Reach USD 2,653.4 Million by 2033 At A 6.5% CAGR, driven by Rising Demand and Advancements in Machine Perfusion Technology | Future Market Insights, Inc.

A liver transplant, also known as a hepatic transplant, is a surgical procedure that is performed when a patient's liver is not capable of performing basic functions, such as synthesizing proteins, carbohydrates, and fats. After the kidney, the liver is the second most frequently transplanted major organ, indicating the seriousness of the liver disease. Despite the fact that the majority of liver transplant operations use livers from deceased donors, it is still possible to obtain a liver from a living person as well (allograft). Current liver transplant demand is substantial, however only critically ill patients are considered for transplants, and these patients are selected based on their critical condition. NEWARK, DE / ACCESSWIRE / December 3, 2024 / The Liver Transplantation Market 2023 to 2033 is witnessing significant growth, reflecting advancements in medical technology and rising prevalence of liver-related diseases. In 2023, the market is valued at USD 1,409.8 million and is projected to reach USD 2,653.4 million by 2033, marking a robust CAGR of 6.5% over the forecast period.The increasing incidence of liver disorders such as cirrhosis and hepatocellular carcinoma is a major driver. According to WHO, nearly 2 million deaths annually are attributed to liver diseases globally. This has spurred a demand for innovative transplantation techniques and improved donor-recipient matching systems.Government and private sector investments in healthcare infrastructure and organ transplantation programs are creating lucrative opportunities. Additionally, the emergence of minimally invasive techniques and the integration of AI-based tools in organ matching and post-operative care have revolutionized the liver transplantation landscape.As the market expands, Asia-Pacific and North America are expected to dominate due to increased healthcare spending and better awareness programs, while advancements in biotechnology continue to drive the innovation curve.What Factors are Driving Growth of the Liver Transplantation Market?As hepatitis A, B, and C incidence increases worldwide, the liver transplantation market is expected to grow in the coming years. A major driving force in the liver transplantation market is the advancement of treatment and the increase in adoption as the most effective method of managing end-stage liver disease.Additionally, reimbursement policies are likely to become increasingly favorable in the near future, leading to a growth in liver transplantation. The fact that organ transplantation is becoming an increasingly popular treatment for organ failure is one of the most significant factors contributing to the growth of the market.During the coming years, the market will experience a great deal of growth due to the rise of passive lifestyles, bad eating habits, excessive drinking, and drug abuse being among the main factors that are driving the market to grow. Various causes of liver failure among the global population as well as the growing geriatric population have increased the demand for liver transplants in various regionsRequest a Sample Copy of This Report Now: https://www.fmisamplereport.com/sample/rep-gb-1281Key Takeaways from Market StudyMarket Size in 2023: USD 1,409.8 millionMarket Size in 2033: USD 2,653.4 millionCAGR (2023-2033): 6.5%Key Growth Regions: North America, Asia-Pacific"The liver transplantation market is entering a dynamic growth phase with the integration of cutting-edge technologies such as AI and robotic surgeries. While the increasing burden of liver diseases presents challenges, the market's rapid adaptation to patient needs and regulatory frameworks ensures a promising future. Public-private collaborations will play a pivotal role in accelerating accessibility and affordability." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)Restricting Factors for the Global Liver Transplantation Market?There are several risks associated with this procedure, including severe bleeding and negative reactions that can be life-threatening, which is a restraint on its use. Several other diseases that can occur as a result of transplants, such as diabetes, high cholesterol, and diarrhea, may impact the market's growth. Staying in a hospital for a long period of time can be expensive, which can hamper the growth of the liver transplantation market.In addition, there are several factors that contributed to the sharp decline in the market's revenue not only in recent years, but also in the future, including the shortage of primary intensive care units, protective equipment, and blood products during transplantation. Over the forecast period, however, liver transplantation market growth can be hindered by a shortage of liver donors, increased waiting lists for liver transplants, and an increase in hospitalization time and costs. As a result, liver transplantation will see a decline in market share in the near future. Component InsightsThe liver transplantation market comprises key components such as immunosuppressive drugs, surgical equipment, and post-operative care services. Among these, immunosuppressive drugs hold the largest share due to their essential role in preventing graft rejection.Growth DriversAdvanced Surgical Techniques: Minimally invasive procedures reduce patient recovery times and risks.Rising Awareness: Growing public understanding of liver health and the importance of transplantation.Supportive Regulations: Policies facilitating faster approvals of new portable medical devices and drugs.Emerging Innovators Are Leading a Transformation in Liver TransplantationA new wave of innovative start-ups, particularly in Western markets, is reshaping the liver transplantation landscape. These companies are introducing cutting-edge medical devices aimed at streamlining transplant procedures, ultimately offering significant benefits to both donors and recipients.Several European firms are pioneering advancements in the preservation of livers donated by both living and deceased individuals. Traditionally, the usable window for a liver after removal from the body is just 12 hours, beyond which the organ is no longer viable for transplantation. Efforts are underway to extend this critical time frame, providing more flexibility and improving patient outcomes.HepaTx, a U.S.-based company, is making strides in the field of regenerative medicine. They are developing stem cell-based therapies as alternatives to liver transplants, targeting patients with late-stage liver diseases. According to their data, only one in thirty-three patients in need of a liver transplant receives an organ in time, highlighting the ongoing challenges in the donor-recipient imbalance despite significant government investments in healthcare.Recent Advancements in Liver TransplantationA ground breaking procedure took place in September 2023 at Jaslok Hospital and Research Center in Mumbai, where a single liver was used to save two lives through a split cadaver liver donation surgery. This method divides the liver into two parts, enabling both an adult and a pediatric patient to benefit from the transplant simultaneously.In another notable development, the Liver4Life team at the University of Zurich has created an innovative blood perfusion machine. This device has the potential to extend the preservation time of a liver to 72 hours, a significant improvement over the previous 12-15 hours. The normothermic perfusion machine mimics the function of a human body by pumping blood to the liver, while supplying essential nutrients and medications to keep the organ in optimal condition before transplantation. This breakthrough has the potential to dramatically improve the viability of donor livers, making a substantial impact on the field.In-Depth Market Analysis: A Complete Reporthttps://www.futuremarketinsights.com/reports/liver-transplantation-marketKey Market PlayersAllosourceConatus Pharmaceuticals Inc.Digna Biotech S.L.Dompe Farmaceutici S.p.A.Isogenis, Inc.RedHill Biopharma Ltd.Thompson SurgicalIntegra Life SciencesBaxter International Inc.XVIVOVirTech BioVital TherapiesHepaTxHumedicsRegional Analysis of Liver Transplantation MarketNorth America: Largest market share with advanced healthcare infrastructure.Europe: Strong government support and rising organ donation rates.Asia-Pacific: Fastest growth driven by increasing medical tourism and awareness.Middle East & Africa: Emerging market due to improved healthcare facilities.Key Segments Profiled in the Global Liver Transplantation MarketBy Treatment Type:Liver Transplantation SurgeryPost-Surgery Anti-Rejection TreatmentCyclosporineTacrolimusSirolimus Prednisone AzathioprineMycophenolate MofetilBy End Use:HospitalsAdult Liver Transplantation CentersAmbulatory Surgical CentersBy Region:North AmericaLatin AmericaEuropeAsia PacificThe Middle East and AfricaAuthorSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Extensive Coverage in the Healthcare Domain:The global liver fibrosis treatment market is expected to surpass an impressive valuation of USD 16.43 billion in 2023 and is projected to exhibit a CAGR of 11% from 2023 to 2033.The injectable drug delivery market is, according to industry analysis, estimated to be around a staggering USD 49.44 billion, as of 2024.The global drug delivery technology market is expected to be valued at USD 43.9 billion in 2023.The global hematopoietic stem cell transplantation market garnered a market value of USD 7 Billion in 2023The cross-species organ transplantation market is projected to be valued at USD 14.8 billion by 2024 and rise to USD 30.5 billion by 2034.The global medical cannula market size is forecast to reach USD 445 Million in 2022.The global medical robot market growth is poised to garner a 12.9% CAGR through 2034.The United States digital ovulation test kits market size is projected to be valued at USD 77.4 million in 2023 and is expected to rise to USD 185.0 million by 2033.The Cardiac Biomarker Diagnostic Test Kits Market size is projected to be worth USD 1,950 million in 2023.The global digital psychotherapeutics market size is projected to be worth US$ 1.06 billion in 2023. Over the next ten years, global digital psychotherapeutics demand is likely to accelerate at 27.6% CAGR.Trending TopicGlobal Skin Substitutes Market Analysis (2024-2034)About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact UsFuture Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website: https://www.futuremarketinsights.comLinkedIn | Twitter | Blogs | YouTubeSOURCE: Future Market Insights, Inc.

19 Nov 2024

·www.prnewswire.com

Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and tissue damage across multiple organ systems, such as the skin, joints, kidneys, heart, and brain. The incidence of autoimmune diseases, including SLE, has been increasing globally, with a significant impact on demand for targeted and effective therapies. LAS VEGAS, Nov. 19, 2024 /PRNewswire/ -- DelveInsight's ' Systemic Lupus Erythematosus Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the systemic lupus erythematosus pipeline domain. Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report DelveInsight's systemic lupus erythematosus pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies for systemic lupus erythematosus treatment. Key systemic lupus erythematosus companies such as Roche, ImmuPharma, UCB, Idorsia Pharmaceuticals, Biogen, AbbVie, Bristol-Myers Squibb, Vera Therapeutics, Beijing Mabworks Biotech Co., Ltd., BeiGene, Jiangsu Renocell Biotech Company, AstraZeneca, Pfizer, Red de Terapia Celular, Kira Pharmacenticals (US), LLC., Jemincare, Galapagos NV, Alumis, argenx, Gilead Sciences, Novartis, Zenas Biopharma, Horizon Therapeutics, Provention Bio, Janssen Research & Development, Eli Lilly and Company, Medsenic, Sanofi, Merck KGaA, Resolve Therapeutics, ILTOO, Janssen, Alpine Immune Sciences, Kezar Life Sciences, Neovacs, Kangpu Biopharmaceuticals, Cartesian Therapeutics, Apellis Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Q32 Bio Inc., Conduit Pharmaceuticals, Miltenyi Biomedicine GmbH, Kyverna Therapeutics, ImmPACT Bio, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Gracell Biotechnologies (Shanghai) Co., Ltd., Cabaletta Bio, Tenet Medicines, Ascentage Pharma Group Inc., InnoCare, Eisai, Sorrento Therapeutics, Carna Bioscience, Yake Biotechnology, Equillium, Daiichi Sankyo Company, SinoMab Bioscience Ltd, Citryll BV, Sareum, Shanghai Junshi Biosciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen Biotech Co., Ltd., Sana Biotechnology, Hoffmann-La Roche, Guangdong Ruishun Biotech Co., Ltd, Shanghai Ming Ju Biotechnology Co., Ltd., Autolus Limited, Nkarta, Inc., Luminary Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Ming Ju Biotechnology, IGM Biosciences, Inc., GlaxoSmithKline, Fate Therapeutics, Cugene Inc., Century Therapeutics, Inc., Cullinan Therapeutics Inc., Juno Therapeutics, Inc., EdiGene Inc., Atara Biotherapeutics, Annexon, Inc., Adicet Therapeutics, Bioray Laboratories, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Juventas Cell Therapy Ltd., Nanjing Bioheng Biotech Co., Ltd., Pregene ShenZhen Biotechnology, Artiva Bio, KeyMed Biosciences, IASO, JW Therapeutics, ROME Therapeutics, Ventus Therapeutics, Allosite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, LongBio Pharma, Amytrx Therapeutics, Corestem, Eliem Therapeutics, SinoMab Bioscience Ltd., and others are evaluating new systemic lupus erythematosus drugs to improve the treatment landscape. Promising systemic lupus erythematosus pipeline therapies such as Obinutuzumab, Lupuzor (IPP-201101), Dapirolizumab pegol, Cenerimod, BIIB059, Upadacitinib, Deucravacitinib, Atacicept, MIL62, Zanubrutinib, RY_SW01 cell injection|Basic treatment, Ravulizumab, Rapcabtagene autoleucel, PF-06823859, Mesenchymal stem cells (MSC), KP104, JMKX000189, Iptacopan, GLPG3667, ESK-001, Elsubrutinib, Efgartigimod alfa, Edecesertib, Ianalumab, Obexelimab (XmAb5871), Daxdilimab (VIB7734), PRV-3279, Nipocalimab, ABBV 599, NKTR-358 (LY3471851), Arscimed, SAR441344, Enpatoran, RSLV-132, Aldesleukin, Daratumumab, Branebrutinib, BMS-986256, ALPN-101, KZR-616, IFNα kinoid, KPG 818, Descartes-08, CFZ533, APL-2, ALXN2050, ADX-097, AZD1656, MB-CART19.1, KYV-101, IMPT-514, GR1603, GC012F Injection, CABA-201, Budoprutug, APG-2575, ICP-022, E6742, ALPN-303, AC0058, Mosunetuzumab, AS-0871, CD19/BCMA CAR T-cells, PF-06835375, EQ001 (Itolizumab), DS-7011a, SM03, CIT-013, SDC-1801, UBP1213, TQB3702, TAK-079, TAK-007, SYNCAR-001, SG301, SC291, RO7507062, RJMty19 (CD19-CAR-DNT cells), Relma-cel, PIT565, Obecabtagene autoleucel (obe-cel), NKX019, LMY-920, KK4277, JWCAR201, Imvotamab, GSK4527363, GSK4347859, FT819, CUG252, CNTY-101, CLN-978, CC-97540, Belantamab, ATHENA CAR-T ATA3219, ANX009, ADI-001, BRL-301, T-cell injection targeting CD19 chimeric antigen receptor, CNCT19, RD06-04, PRG-2311, PRG-1801, AlloNK, CM313, CT103A, JWCAR 029, Research program: endogenous reverse transcriptase inhibitors, VENT 03, ONT01, BCMA-CD19 cCAR T cells, CB-010, LP-005, AMTX 100, CE211AT15, TN-119, SN1011, QX002N, RSLV-145, Recombinant human plasma gelsolin, LN-008, TST 008, IBL 100s, and others are under different phases of systemic lupus erythematosus clinical trials. In October 2024, the FDA approved the investigational new drug (IND) application for Cullinan Therapeutics' CLN-978 to treat systemic lupus erythematosus (SLE). In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administration (FDA) had granted fast-track designation to CAR T-cell therapy CB-010 for systemic lupus erythematosus (SLE). In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus. In August 2024, Conduit Pharmaceuticals announced they will be conducting a Phase IIa clinical trial to evaluate AZD1656 for the treatment of multiple autoimmune diseases, including systemic lupus erythematosus (SLE). In July 2024, the first individual received the therapy Descartes-08 to treat systemic lupus erythematosus. This therapy has been previously administered to patients with myasthenia gravis, a long-term autoimmune disorder characterized by muscle weakness. In February 2024, Idorsia Pharmaceuticals formed a major global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, on a global scale. Request a sample and discover the recent advances in systemic lupus erythematosus treatment drugs @ Systemic Lupus Erythematosus Pipeline Report The systemic lupus erythematosus pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage systemic lupus erythematosus drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the systemic lupus erythematosus clinical trial landscape. Systemic Lupus Erythematosus Overview Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues in various parts of the body. The exact cause of SLE is unknown, but it is believed to result from a combination of genetic, environmental, and hormonal factors. Common triggers include infections, sunlight exposure, and certain medications. Women, particularly of childbearing age, are more commonly affected. Symptoms of SLE vary widely and can affect many organ systems, leading to a wide range of clinical presentations. Common symptoms include fatigue, joint pain, skin rashes, photosensitivity, and fever. More severe cases can affect the kidneys, heart, lungs, and central nervous system, potentially leading to life-threatening complications. Diagnosis of SLE is based on a combination of clinical features and laboratory tests. The antinuclear antibody (ANA) test is a common initial screening tool, but additional tests like anti-double stranded DNA (anti-dsDNA) and anti-Smith antibodies, as well as assessments of kidney and liver function, are often necessary. Diagnosis can be challenging because SLE symptoms often mimic those of other diseases. Treatment for SLE focuses on managing symptoms and preventing flares. Mild cases may be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and antimalarial drugs like hydroxychloroquine. More severe cases may require corticosteroids, immunosuppressive drugs such as azathioprine, methotrexate, or newer biologics like belimumab. Lifestyle modifications, such as avoiding excessive sun exposure and managing stress, are also essential in controlling the disease. Find out more about systemic lupus erythematosus treatment drugs @ Drugs for Systemic Lupus Erythematosus Treatment A snapshot of the Systemic Lupus Erythematosus Pipeline Drugs mentioned in the report: Learn more about the emerging systemic lupus erythematosus pipeline therapies @ Systemic Lupus Erythematosus Clinical Trials Systemic Lupus Erythematosus Therapeutics Assessment The systemic lupus erythematosus pipeline report proffers an integral view of the systemic lupus erythematosus emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Systemic Lupus Erythematosus Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Cell death inhibitors, Cell death stimulants, Immunomodulators, CD40 ligand inhibitors, Sphingosine 1 phosphate receptor modulators, Calcineurin inhibitors, Immunosuppressants, Janus kinase 1 inhibitors, TYK2 kinase inhibitors, B cell activating factor inhibitors, Tumour necrosis factor ligand superfamily member 13 inhibitors Key Systemic Lupus Erythematosus Companies: Roche, ImmuPharma, UCB, Idorsia Pharmaceuticals, Biogen, AbbVie, Bristol-Myers Squibb, Vera Therapeutics, Beijing Mabworks Biotech Co., Ltd., BeiGene, Jiangsu Renocell Biotech Company, AstraZeneca, Pfizer, Red de Terapia Celular, Kira Pharmacenticals (US), LLC., Jemincare, Galapagos NV, Alumis, argenx, Gilead Sciences, Novartis, Zenas Biopharma, Horizon Therapeutics, Provention Bio, Janssen Research & Development, Eli Lilly and Company, Medsenic, Sanofi, Merck KGaA, Resolve Therapeutics, ILTOO, Janssen, Alpine Immune Sciences, Kezar Life Sciences, Neovacs, Kangpu Biopharmaceuticals, Cartesian Therapeutics, Apellis Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Q32 Bio Inc., Conduit Pharmaceuticals, Miltenyi Biomedicine GmbH, Kyverna Therapeutics, ImmPACT Bio, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Gracell Biotechnologies (Shanghai) Co., Ltd., Cabaletta Bio, Tenet Medicines, Ascentage Pharma Group Inc., InnoCare, Eisai, Sorrento Therapeutics, Carna Bioscience, Yake Biotechnology, Equillium, Daiichi Sankyo Company, SinoMab Bioscience Ltd, Citryll BV, Sareum, Shanghai Junshi Biosciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen Biotech Co., Ltd., Sana Biotechnology, Hoffmann-La Roche, Guangdong Ruishun Biotech Co., Ltd, Shanghai Ming Ju Biotechnology Co., Ltd., Autolus Limited, Nkarta, Inc., Luminary Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Ming Ju Biotechnology, IGM Biosciences, Inc., GlaxoSmithKline, Fate Therapeutics, Cugene Inc., Century Therapeutics, Inc., Cullinan Therapeutics Inc., Juno Therapeutics, Inc., EdiGene Inc., Atara Biotherapeutics, Annexon, Inc., Adicet Therapeutics, Bioray Laboratories, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Juventas Cell Therapy Ltd., Nanjing Bioheng Biotech Co., Ltd., Pregene ShenZhen Biotechnology, Artiva Bio, KeyMed Biosciences, IASO, JW Therapeutics, ROME Therapeutics, Ventus Therapeutics, Allosite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, LongBio Pharma, Amytrx Therapeutics, Corestem, Eliem Therapeutics, SinoMab Bioscience Ltd., and others. Key Systemic Lupus Erythematosus Pipeline Therapies: Obinutuzumab, Lupuzor (IPP-201101), Dapirolizumab pegol, Cenerimod, BIIB059, Upadacitinib, Deucravacitinib, Atacicept, MIL62, Zanubrutinib, RY_SW01 cell injection|Basic treatment, Ravulizumab, Rapcabtagene autoleucel, PF-06823859, Mesenchymal stem cells (MSC), KP104, JMKX000189, Iptacopan, GLPG3667|Placebo, ESK-001, Elsubrutinib, Efgartigimod alfa, Edecesertib, Ianalumab, Obexelimab (XmAb5871), Daxdilimab (VIB7734), PRV-3279, Nipocalimab, ABBV 599, NKTR-358 (LY3471851), Arscimed, SAR441344, Enpatoran, RSLV-132, Aldesleukin, Daratumumab, Branebrutinib, BMS-986256, ALPN-101, KZR-616, IFNα kinoid, KPG 818, Descartes-08, CFZ533, APL-2, ALXN2050, ADX-097, AZD1656, MB-CART19.1, KYV-101, IMPT-514, GR1603, GC012F Injection, CABA-201, Budoprutug, APG-2575, ICP-022, E6742, ALPN-303, AC0058, Mosunetuzumab, AS-0871, CD19/BCMA CAR T-cells, PF-06835375, EQ001 (Itolizumab), DS-7011a, SM03, CIT-013, SDC-1801, UBP1213, TQB3702, TAK-079, TAK-007, SYNCAR-001, SG301, SC291, RO7507062, RJMty19 (CD19-CAR-DNT cells), Relma-cel, PIT565, Obecabtagene autoleucel (obe-cel), NKX019, LMY-920, KK4277, JWCAR201, Imvotamab, GSK4527363, GSK4347859, FT819, CUG252, CNTY-101, CLN-978, CC-97540, Belantamab, ATHENA CAR-T ATA3219, ANX009, ADI-001, BRL-301, T-cell injection targeting CD19 chimeric antigen receptor, CNCT19, RD06-04, PRG-2311, PRG-1801, AlloNK, CM313, CT103A, JWCAR 029, Research program: endogenous reverse transcriptase inhibitors, VENT 03, ONT01, BCMA-CD19 cCAR T cells, CB-010, LP-005, AMTX 100, CE211AT15, TN-119, SN1011, QX002N, RSLV-145, Recombinant human plasma gelsolin, LN-008, TST 008, IBL 100s, and others. Dive deep into rich insights for new drugs for systemic lupus erythematosus treatment, visit @ Systemic Lupus Erythematosus Drugs Table of Contents For further information on the systemic lupus erythematosus pipeline therapeutics, reach out @ Systemic Lupus Erythematosus Treatment Drugs Related Reports Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Epidemiology Systemic Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted SLE epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, NOVARTIS, CABALETTA BIO, among others. Lupus Nephritis Pipeline Lupus Nephritis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Inflection Biosciences, Equillium, Roche, Horizon Therapeutics, BeiGene, Janssen Research & Development, ImmPACT Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Phase 2Fast TrackCell Therapy

100 Deals associated with Azathioprine

External Link

KEGG	Wiki	ATC	Drug Bank
D00238	Azathioprine	L04AX01	DB00993

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Behcet Syndrome	EU	Lipomed AG	21 Jun 2021
Behcet Syndrome	IS	Lipomed AG	21 Jun 2021
Behcet Syndrome	LI	Lipomed AG	21 Jun 2021
Behcet Syndrome	NO	Lipomed AG	21 Jun 2021
Chronic idiopathic thrombocytopenic purpura	EU	Lipomed AG	21 Jun 2021
Chronic idiopathic thrombocytopenic purpura	IS	Lipomed AG	21 Jun 2021
Chronic idiopathic thrombocytopenic purpura	LI	Lipomed AG	21 Jun 2021
Chronic idiopathic thrombocytopenic purpura	NO	Lipomed AG	21 Jun 2021
Inflammatory Bowel Diseases	EU	Lipomed AG	21 Jun 2021
Inflammatory Bowel Diseases	IS	Lipomed AG	21 Jun 2021
Inflammatory Bowel Diseases	LI	Lipomed AG	21 Jun 2021
Inflammatory Bowel Diseases	NO	Lipomed AG	21 Jun 2021
Multiple sclerosis relapse	EU	Lipomed AG	21 Jun 2021
Multiple sclerosis relapse	IS	Lipomed AG	21 Jun 2021
Multiple sclerosis relapse	LI	Lipomed AG	21 Jun 2021
Multiple sclerosis relapse	NO	Lipomed AG	21 Jun 2021
Myasthenia Gravis	EU	Lipomed AG	21 Jun 2021
Myasthenia Gravis	IS	Lipomed AG	21 Jun 2021
Myasthenia Gravis	LI	Lipomed AG	21 Jun 2021
Myasthenia Gravis	NO	Lipomed AG	21 Jun 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW	Not Applicable	Inflammatory Bowel Diseases 6-TGN \| 6-MMP \| FC (fecal calprotectin)	237	Low-dose azathioprine plus allopurinol	vzdwkvoxmg(wasynityoo): OR = 2.46 (95% CI, 1.43 - 4.25), P-Value = 0.001	Positive	13 Oct 2024
				Azathioprine monotherapy
UEGW	Not Applicable	Hepatitis, Autoimmune First line	265	Mycophenolate mofetil (MMF)	qxdtcihyzm(xbbybrhcpr): OR = 3.81 (95% CI, 1.98 - 7.36), P-Value = < 0.0001 View more	Positive	13 Oct 2024
				Azathioprine (AZA)
EULAR2024	Not Applicable	Systemic Lupus Erythematosus	-	Hydroxychloroquine (HCQ)	pyhinhatoh(kntljczavx) = xiijxtybrk eotnwtkywj (okxibnujyw, 4 - 38) View more	-	05 Jun 2024
				Methotrexate (MTX)	pyhinhatoh(kntljczavx) = rovnckajea eotnwtkywj (okxibnujyw, 6 - 29) View more
EULAR2024	Not Applicable	Lupus Nephritis	-	Azathioprine	bmoasxgqsm(uiqqsbquem) = drvxetmmoe ylyylavysz (iwftlwjylk )	-	05 Jun 2024
EHA2024	Not Applicable	Anemia, Sickle Cell	20	Azathioprine/Hydroxyurea Preconditioning + Alemtuzumab/TBI Conditioning	manrvbvpbc(gsqhxiioaa) = One patient developed steroid-responsive grade II intestinal acute graft-versus-host disease poeyngveou (zodnljztyh ) View more	Positive	14 May 2024
NCT02900443 (Pubmed \| J Hepatol)	Phase 4	Hepatitis, Autoimmune	70	Mycophenolate mofetil	kqoiidwqtn(hneqghlauj) = mbzbzvaysl tiygfivloa (fdahgitiss, 4.0 - 46.7)	Positive	01 Apr 2024
				Azathioprine	kqoiidwqtn(hneqghlauj) = rimgzffejr tiygfivloa (fdahgitiss ) View more
Pubmed \| Lancet Neurol	Not Applicable	Myasthenia Gravis	-	Azathioprine	kxjlxlahvn(oekhepteac) = seven [15%] of 48 pqswrjbhtm (bjgpcxdzit ) View more	-	01 Mar 2024
				Mycophenolate mofetil
NCT02900443 (CAMARO TRIAL, UEGW)	Phase 4	Hepatitis, Autoimmune	70	Mycophenolate Mofetil (MMF) plus prednis(ol)one	tcxfovtwxe(ssfxhpprpt) = nwunkkyjvl upzyraqtsr (masnunqdze )	Positive	15 Oct 2023
				Azathioprine plus prednis(ol)one	tcxfovtwxe(ssfxhpprpt) = iqheteqdwn upzyraqtsr (masnunqdze )
WCD2023	Not Applicable	-	80	Cyclosporine	ldnbawucte(nbimpkolbt) = oychvutkpp rwcqrfdhvf (bvnzsjpuxy )	Positive	04 Jul 2023
				Azathioprine	ldnbawucte(nbimpkolbt) = ftqlmrzann rwcqrfdhvf (bvnzsjpuxy )
WCD2023	Not Applicable	Pemphigus	-	Azathioprine	eualkfqifh(rmrtrqhzcb) = diffuse non-scarring hair loss hdssnrried (uimgzunzcr ) View more	-	03 Jul 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis